Imagine finding a drug that could augment the effect of chemotherapy on a huge range of very difficult to treat solid tumours (eg pancreatic, prostate, breast). Imagine this drug also shows amazing promise in treating firbrotic diseases (eg pulmonary fibrosis, post surgical scarring). What if you found the Phase 1 demonstrated not only safety and easy oral dosing of this easy to manufacture small molecule but also proven effect on the enzyme in question at those doses (FAK).
Also:
-Funded for phase 2
-Phase 2 for both pancreatic cancer and pulmonary fibrosis commencing 2022
-Stellar board that has hit every milestone as promised
- Alan Moss AO (yes the Macquarie bank guy) is the biggest shareholder via holding companies and puts his hand in his deep pocket for any funding needed.
-World leading clinical expert as CMO
-Garvin institute collaboration
-ATXO options (Dec 23) trade on asx if you like to leverage up.
Have you missed the boat? No way! ATX has a MC of 31M! Positive phase 2 (in either study) should see it rocket to MC 3-500M.
The science and numbers is in the investor presentation- you can make up your own mind: https://www.ampliatx.com/site/PDF/a...99cdeb/AmpliaInvestorPresentationFebruary2022
Cheers
Rob
Also:
-Funded for phase 2
-Phase 2 for both pancreatic cancer and pulmonary fibrosis commencing 2022
-Stellar board that has hit every milestone as promised
- Alan Moss AO (yes the Macquarie bank guy) is the biggest shareholder via holding companies and puts his hand in his deep pocket for any funding needed.
-World leading clinical expert as CMO
-Garvin institute collaboration
-ATXO options (Dec 23) trade on asx if you like to leverage up.
Have you missed the boat? No way! ATX has a MC of 31M! Positive phase 2 (in either study) should see it rocket to MC 3-500M.
The science and numbers is in the investor presentation- you can make up your own mind: https://www.ampliatx.com/site/PDF/a...99cdeb/AmpliaInvestorPresentationFebruary2022
Cheers
Rob
